Assessing Pancreatic Cancer Risk Associated with Dipeptidyl Peptidase 4 Inhibitors: Data Mining of FDA Adverse Event Reporting System (FAERS)

Background: Identifying cancer risks associated with medicinal agents plays an important role in cancer control and prevention. Case reports of cancers associated with pharmacotherapy have been escalating in the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective of this study is to assess the risk of pancreatic cancer associated with anti-diabetic drugs of dipeptidyl peptidase 4 (DPP 4) inhibitors with or without combination of metformin. Methods: Using the FAERS public database, the adverse event reports (ADRs) associated with widely used DPP 4 inhibitors with or without combination of metformin were generated and evaluated. Standardized pharmacovigilance tools were applied to detect the signal for cancer risks by calculating the proportional reporting ratio (PRR) and the reporting odds ratio (ROR). Results: Among 12618 ADRs associated with sitagliptin from 2007 to 2011, there were 223 cases of cancer. There was a significant correlation between the cancer reporting ratio and the time (R=0.796, P<0.001). Pancreatic cancers accounted for 22% of all combined cancer adverse events. Pharmacovigilance assessment from 2007 to 2012 indicated that there was a significant risk of pancreatic cancer associated with DPP 4 inhibitors treatment (ROR=5.922). Interestingly, minimal risk of pancreatic cancer risk was associated with metformin (ROR=1.214). Combination of DPP 4 inhibitor sitagliptin with metformin correlates with significantly lower risk of pancreatic cancer compared to sitagliptin treatment without metformin (OR=0.277, 95%CI: 0.210-0.365). Interpretation: There was a significant signal of pancreatic cancer risk associated with DPP 4 inhibitor treatment. For the first time we demonstrated that combination with metformin significantly reduced the risk signal of pancreatic cancer associated with DPP 4 inhibitors in FAERS. Considering the limitation of the FAERS, this study implied the potential strategy for cancer control and prevention in diabetic patients, and provided directions for future clinical studies.

[1]  Iraklis Varlamis,et al.  Use of social media by healthcare professionals in Greece: an exploratory study , 2012, Int. J. Electron. Heal..

[2]  R. Elashoff,et al.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.

[3]  W. Chou,et al.  Social Media Use in the United States: Implications for Health Communication , 2009, Journal of medical Internet research.

[4]  Xilin Yang,et al.  Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry , 2010, Diabetes.

[5]  B. Hoogwerf,et al.  Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. , 2012, Clinical therapeutics.

[6]  Bryant Thomas Karras,et al.  Design and Implementation of Cell-PREVEN: A Real-Time Surveillance System for Adverse Events Using Cell Phones in Peru , 2005, AMIA.

[7]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[8]  Stephanie J. Reisinger,et al.  Drug-versus-Drug Adverse Event Rate Comparisons , 2009, Drug safety.

[9]  M. Pendergrass,et al.  Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin , 2010, Diabetes Care.

[10]  A. Banerjee,et al.  Web-Based Patient-Reported Outcomes in Drug Safety and Risk Management , 2012, Drug Safety.

[11]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[12]  S. Zucker,et al.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. , 2006, Cancer research.

[13]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[14]  Beatrice A. Golomb,et al.  A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class , 2012, PloS one.

[15]  H. Kennedy,et al.  Pancreatic cancer: a review of the evidence on causation. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[17]  Yasushi Okuno,et al.  Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations , 2011, International journal of medical sciences.

[18]  H. Yabuuchi,et al.  Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS , 2011, International journal of medical sciences.

[19]  R. Meyboom,et al.  Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase , 2011, Diabetes Care.

[20]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[21]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.

[22]  Yasushi Okuno,et al.  Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS , 2011, Journal of experimental & clinical cancer research : CR.

[23]  R. Elble,et al.  Lung Endothelial Dipeptidyl Peptidase IV Promotes Adhesion and Metastasis of Rat Breast Cancer Cells via Tumor Cell Surface-associated Fibronectin* , 1998, The Journal of Biological Chemistry.

[24]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[25]  C. Pamer,et al.  Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. , 2006, Journal of child and adolescent psychopharmacology.

[26]  R. Hoover,et al.  Drug‐induced cancer , 1981, Journal of the National Cancer Institute.

[27]  正博 頭金.  FDA adverse event reporting system (FAERS) , 2015 .

[28]  Aune Moro,et al.  Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts , 2013, Pancreas.

[29]  A Lawrence Gould,et al.  Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.

[30]  P. Stolley,et al.  Nonhormonal drugs and cancer. , 1995, Environmental health perspectives.

[31]  Stephen Mifsud,et al.  Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? , 2011, Drug safety.

[32]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[33]  N. Hawkes.  Journal withdraws article after complaints from drug manufacturers , 2011, BMJ : British Medical Journal.

[34]  W. DuMouchel,et al.  Novel Statistical Tools for Monitoring the Safety of Marketed Drugs , 2007, Clinical pharmacology and therapeutics.

[35]  E. Vandewater,et al.  Media, social networking, and pediatric obesity. , 2011, Pediatric clinics of North America.